Literature DB >> 2407764

Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects.

L Cynober1, C Coudray-Lucas, J P de Bandt, J Guéchot, C Aussel, M Salvucci, J Giboudeau.   

Abstract

Ornithine alpha-ketoglutarate (OKG) has been useful as an adjuvant of enteral and parenteral nutrition. However, its metabolism and mechanism of action remain unclear although it is known that alpha-ketoglutarate (alpha KG) and ornithine (ORN) follow, in part, common metabolic pathways. Six fasting healthy male subjects underwent three separate oral load tests: (i) they received 10 g of OKG (i.e., 3.6 g of alpha KG and 6.4 g of ORN); (ii) 6.4 g of ORN as ornithine hydrochloride, and (iii) 3.6 g of alpha KG as calcium alpha-ketoglutarate. Blood was drawn 15 times over a five-hour period for measurements of plasma amino acids, alpha KG, insulin, and glucagon. After OKG and ORN administration, plasma ORN peaked at 60-75 min (494 +/- 91 and 541 +/- 85 mumol/L). The increase in plasma alpha KG was very small. OKG, alpha KG, and ORN all increased glutamate concentrations at 60 min (mean: +43%, +68%, +68%, respectively, p less than 0.05 compared to basal values). However, only OKG increased proline and arginine levels at 60 min (mean: +35%, p less than 0.01 and mean: +41%, p less than 0.05). Furthermore, glutamate, proline, and arginine concentrations correlated linearly with ornithine levels at 60 min. Finally, OKG increased insulinemia and glucagonemia (mean: +24% at 15 min, p less than 0.05 and +30% at 60 min, p less than 0.01, respectively). These data provide evidence that the combination of ORN and alpha KG modifies amino acid metabolism in a way which is not observed when they are administered separately. In addition, the OKG-mediated increase in insulin levels probably does not appear to result from a direct action of ORN on pancreatic secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407764     DOI: 10.1080/07315724.1990.10720343

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  7 in total

1.  Anaplerotic therapy in propionic acidemia.

Authors:  Nicola Longo; Leisa B Price; Eduard Gappmaier; Nancy L Cantor; Sharon L Ernst; Carrie Bailey; Marzia Pasquali
Journal:  Mol Genet Metab       Date:  2017-07-12       Impact factor: 4.797

2.  Action of ornithine alpha ketoglutarate on DNA synthesis by human fibroblasts.

Authors:  M Vaubourdolle; M Salvucci; C Coudray-Lucas; J Agneray; L Cynober; O G Ekindjian
Journal:  In Vitro Cell Dev Biol       Date:  1990-02

3.  Ornithine alpha-ketoglutarate: could it be a new therapeutic option for sarcopenia?

Authors:  S Walrand
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

4.  Effect of ornithine alpha-ketoglutarate on glutamine pools in burn injury: evidence of component interaction.

Authors:  L Cynober; E Lasnier; J Le Boucher; A Jardel; C Coudray-Lucas
Journal:  Intensive Care Med       Date:  2007-01-18       Impact factor: 17.440

5.  Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets.

Authors:  L Castillo; T E Chapman; M Sanchez; Y M Yu; J F Burke; A M Ajami; J Vogt; V R Young
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 6.  Can arginine and ornithine support gut functions?

Authors:  L Cynober
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 7.  Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use.

Authors:  Barbara Zdzisińska; Aleksandra Żurek; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-06-20       Impact factor: 4.291

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.